Peptide

Thymalin

Thymalin (thymus peptide complex)

A thymus-derived peptide complex from the Khavinson group. Positioned as an immunomodulator for aging thymic involution. Cytomax-format precursor to the isolated dipeptide Thymogen.

Editor approved

Summary Can Thymalin slow aging or strengthen the immune system? Show / hide ↓

Thymalin is a mixture of small protein fragments made from thymus tissue, an organ that helps train the immune system. It is used in Russia in short injection courses, including after chemotherapy, infections, and in older people. Russian studies report better immune-cell measurements, fewer respiratory infections, and lower death rates, but the strongest claims come from studies that were not modern, blinded trials. No independent Western trials have confirmed these results. Some users take 5 to 10 mg daily for 10 days, but there is not enough reliable evidence to know whether this improves health or lifespan.

What this means for you: Thymalin has a plausible purpose for immune problems linked to aging, but the evidence is weak and comes mainly from Russian studies. It is not well supported as a general longevity treatment.

weak evidence

Research snapshot No human clinical trials in indexed journals. Khavinson thymus peptide.

Updated 2026-08-11

Thymalin is a Russian peptide bioregulator targeting the immune system. Evidence is limited to Russian-language studies and animal experiments. No independent human trials in Western journals confirm its immune-modulating claims.

Evidence tierTier 5, Mechanistic hypothesis, minimal human data

Typical doseCommon protocol: 5 to 10 mg per day intramuscular, 10 consecutive days, one to two courses per year.

SafetyReported side effects in Russian literature are mild and rare. Long-term independent safety data does not exist.

Categorypeptide bioregulator (Cytomax)

Last verified2026-08-05

Thymalin sits at the intersection of Soviet-era immunology and the modern Khavinson bioregulator program. The thymus is a paradigmatic case for the bioregulator theory: it is one of the earliest organs to involute with age, its output of naive T cells declines steeply, and this thymic involution is causally linked to immunosenescence and increased infection and cancer risk in older adults.

Thymalin has been used clinically in Russia since the late 1970s in short intramuscular courses for immune restoration after chemotherapy, infection recovery, and general aging support. Reported effects include restoration of CD4/CD8 T-cell ratios in aged subjects, normalization of naive T-cell output, and reduction of respiratory infection frequency in elderly cohorts.

The most striking single study from the Khavinson group is a long-term follow-up in elderly Russian subjects: cycled Thymalin over multiple years was associated with substantial reductions in all-cause mortality compared with untreated controls. As with all the Khavinson mortality claims, this was not a modern double-blind RCT and has not been independently replicated.

The related Cytogen product Thymogen is the isolated Glu-Trp dipeptide, sold both in Russia and internationally. Thymogen has cleaner pharmacology (single defined molecule, better characterized pharmacokinetics) but a narrower reported effect than the broader Thymalin extract, which is consistent with the general Cytomax versus Cytogen pattern in this family.

Inside the biohacker community, Thymalin is used as a 10 day intramuscular course of 5 to 10 mg per day, one or two courses per year, aimed at immune support and general resilience. Some users cycle it before high-exposure travel or during recovery from infection. Reported side effects are minimal.

Our position: Thymalin sits at Tier 5 for the broad longevity claims and Tier 4 for the narrow immune-support use in elderly subjects, based on the Russian clinical use and the mechanistic plausibility of counteracting thymic involution. Independent Western replication would substantially clarify the picture.

Related in the encyclopedia

Further reading